Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone

INTRODUCTION: Prostate cancer (PC) is the second leading cause of cancer death among US men and accounts for considerable healthcare expenditures. We evaluated economic outcomes in men with chemotherapy-naïve metastatic castration-resistant PC (mCRPC) treated with enzalutamide or abiraterone acetate...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Adv Ther
Prif Awduron: Ramaswamy, Krishnan, Lechpammer, Stanislav, Mardekian, Jack, Huang, Ahong, Schultz, Neil M., Sandin, Rickard, Wang, Li, Baser, Onur, George, Daniel J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Springer Healthcare 2020
Pynciau:
Original Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7467473/
https://ncbi.nlm.nih.gov/pubmed/32112280
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-020-01260-x
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg